Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Inezetamab, an antibody targeting CD40 × MSLN.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Enuzovimab, an antibody targeting SARS-CoV-2 Spike RBD.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Tilvestamab, an antibody targeting AXL.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Bapotulimab, an antibody targeting ILDR2.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Vopikitug, an antibody targeting IL2RA.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Gorivitug, an antibody targeting SARS-CoV-2 Spike RBD.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Zifibancimig, an antibody targeting ANPT2 × VEGF-A.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Linavonkibart, an antibody targeting TGFB1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Englumafusp, an antibody targeting CD19.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Trabikibart, an antibody targeting CSF2RB.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Oberotatug, an antibody targeting LY75.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Evunzekibart, an antibody targeting 4-1BB.